Pharmaceuticals, Biotechnology and Life Sciences
As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction…
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORM Paris, January 29, 2025, 7pm CET AB Science SA…
ENGLEWOOD, Colo., Jan. 29, 2025 (GLOBE NEWSWIRE) — Ampio Pharmaceuticals, Inc. (the “Company” or “Ampio”) has released the following notice…
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris – France,…
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) — The Special Committee of the Board of Directors of 23andMe Holding Co.…
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan.…
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that…
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction…
Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues…